Greif (GEF) Hit By Merrill Lynch Downgrade; NxStage Medical, Inc. (NXTM) Had 2 Bullish Analysts

September 1, 2017 - By Darrin Black

Among 7 analysts covering Greif (NYSE:GEF), 3 have Buy rating, 2 Sell and 2 Hold. Therefore 43% are positive. Greif has $58 highest and $40 lowest target. $51.75’s average target is -14.39% below currents $60.45 stock price. Greif had 26 analyst reports since August 11, 2015 according to SRatingsIntel. Sidoti initiated the stock with “Buy” rating in Friday, March 17 report. The firm has “Buy” rating by Bank of America given on Friday, January 27. As per Monday, November 21, the company rating was downgraded by Wells Fargo. The stock has “Buy” rating by Bank of America on Tuesday, September 6. The firm earned “Hold” rating on Friday, July 14 by BMO Capital Markets. BMO Capital Markets maintained Greif, Inc. (NYSE:GEF) on Monday, April 24 with “Hold” rating. The company was upgraded on Wednesday, September 2 by BMO Capital Markets. Robert W. Baird maintained Greif, Inc. (NYSE:GEF) on Friday, June 9 with “Buy” rating. The company was upgraded on Wednesday, January 4 by Robert W. Baird. DA Davidson upgraded the stock to “Buy” rating in Tuesday, August 18 report.

Among 9 analysts covering NxStage Medical (NASDAQ:NXTM), 2 have Buy rating, 1 Sell and 6 Hold. Therefore 22% are positive. NxStage Medical had 15 analyst reports since November 4, 2015 according to SRatingsIntel. The rating was maintained by BTIG Research with “Buy” on Tuesday, June 6. The rating was downgraded by Canaccord Genuity on Monday, August 7 to “Hold”. Jefferies downgraded the stock to “Hold” rating in Tuesday, August 8 report. Piper Jaffray reinitiated NxStage Medical, Inc. (NASDAQ:NXTM) on Thursday, March 31 with “Overweight” rating. As per Monday, August 7, the company rating was downgraded by Craig Hallum. The firm has “Market Perform” rating given on Tuesday, August 22 by Leerink Swann. On Friday, December 18 the stock rating was initiated by BTIG Research with “Buy”. On Friday, August 11 the stock rating was downgraded by BTIG Research to “Neutral”. As per Monday, August 7, the company rating was maintained by Northland Capital. The firm has “Outperform” rating given on Tuesday, June 28 by Northland Capital. See NxStage Medical, Inc. (NASDAQ:NXTM) latest ratings:

22/08/2017 Broker: Leerink Swann Old Rating: Outperform New Rating: Market Perform Downgrade
11/08/2017 Broker: BTIG Research Old Rating: Buy New Rating: Neutral Downgrade
08/08/2017 Broker: Jefferies Old Rating: Buy New Rating: Hold Downgrade
07/08/2017 Broker: Canaccord Genuity Rating: Hold Downgrade
07/08/2017 Broker: Northland Capital Rating: Hold New Target: $30.0000 Maintain
07/08/2017 Broker: Craig Hallum Rating: Hold Downgrade
06/06/2017 Broker: BTIG Research Rating: Buy New Target: $27.0000 Maintain
27/06/2017 Broker: Craig Hallum Rating: Buy New Target: $32 Initiates Coverage On

Since March 3, 2017, it had 0 insider buys, and 14 insider sales for $2.05 million activity. $82,260 worth of NxStage Medical, Inc. (NASDAQ:NXTM) was sold by Burbank Jeffrey H. 15,723 NxStage Medical, Inc. (NASDAQ:NXTM) shares with value of $434,898 were sold by Swan Winifred L. On Wednesday, May 3 Turk Joseph E Jr sold $29,950 worth of NxStage Medical, Inc. (NASDAQ:NXTM) or 1,000 shares. 14,397 shares were sold by Brown Robert S., worth $382,960. TOWSE MATTHEW W sold $91,848 worth of stock or 4,300 shares. Shares for $27,930 were sold by MOORE CRAIG W on Thursday, March 16.

NxStage Medical, Inc. is a medical technology company. The company has market cap of $1.82 billion. The Firm develops, makes and markets services and products for patients suffering from chronic or acute kidney failure. It currently has negative earnings. It operates through three divisions.

It closed at $28 lastly. It is down 21.18% since September 1, 2016 and is uptrending. It has outperformed by 4.48% the S&P500.

Investors sentiment increased to 1.14 in Q4 2016. Its up 0.10, from 1.04 in 2016Q3. It improved, as 15 investors sold NxStage Medical, Inc. shares while 67 reduced holdings. 31 funds opened positions while 39 raised stakes. 59.80 million shares or 3.37% less from 61.88 million shares in 2016Q3 were reported. Moreover, Rhenman And Partners Asset Mngmt Ab has 0.8% invested in NxStage Medical, Inc. (NASDAQ:NXTM) for 158,901 shares. Citadel owns 0% invested in NxStage Medical, Inc. (NASDAQ:NXTM) for 48,453 shares. Price T Rowe Assoc Incorporated Md reported 8,275 shares. Victory Cap Mgmt Inc has invested 0.09% in NxStage Medical, Inc. (NASDAQ:NXTM). Great West Life Assurance Can reported 0% of its portfolio in NxStage Medical, Inc. (NASDAQ:NXTM). Jpmorgan Chase stated it has 0% of its portfolio in NxStage Medical, Inc. (NASDAQ:NXTM). Barclays Public Ltd Com accumulated 5,689 shares or 0% of the stock. Amer Gru Inc invested in 0% or 36,616 shares. Goldman Sachs Group reported 43,564 shares stake. 2,250 are held by Whittier Co. New York-based Gilder Gagnon Howe And Comm Lc has invested 2.97% in NxStage Medical, Inc. (NASDAQ:NXTM). 400,000 are owned by Polar Capital Llp. Bancshares Of Mellon holds 0% or 636,952 shares in its portfolio. California-based First Republic Investment Mgmt has invested 0% in NxStage Medical, Inc. (NASDAQ:NXTM). Pier Cap Llc holds 1.02% or 214,363 shares in its portfolio.

It closed at $60.45 lastly. It is down 67.37% since September 1, 2016 and is uptrending. It has outperformed by 50.67% the S&P500.

Since June 13, 2017, it had 3 insider buys, and 0 sales for $935,154 activity. Hilsheimer Lawrence A. also bought $409,269 worth of Greif, Inc. (NYSE:GEF) on Tuesday, June 13. 4,400 shares were bought by WATSON PETER G, worth $253,029 on Tuesday, June 13. 5,000 shares were bought by NORTON PATRICK J, worth $272,856 on Tuesday, June 13.

Investors sentiment decreased to 0.78 in 2016 Q4. Its down 0.24, from 1.02 in 2016Q3. It fall, as 16 investors sold Greif, Inc. shares while 59 reduced holdings. 31 funds opened positions while 67 raised stakes. 23.00 million shares or 0.83% more from 22.81 million shares in 2016Q3 were reported. Point72 Asia (Hong Kong) Limited accumulated 1,378 shares. Cornercap Inv Counsel Incorporated stated it has 0.1% in Greif, Inc. (NYSE:GEF). Heartland Advsr Incorporated stated it has 202,552 shares or 0.57% of all its holdings. Cubist Systematic Strategies Limited Liability Company stated it has 3,001 shares. Aqr Capital Mgmt Limited Company owns 0.02% invested in Greif, Inc. (NYSE:GEF) for 316,220 shares. Geode Cap Llc has invested 0.01% in Greif, Inc. (NYSE:GEF). Mckinley Capital Ltd Liability Delaware invested in 0% or 1,500 shares. Blackrock Mngmt Limited Com holds 0.01% in Greif, Inc. (NYSE:GEF) or 178,913 shares. Swiss Commercial Bank owns 0% invested in Greif, Inc. (NYSE:GEF) for 42,400 shares. Creative Planning stated it has 461 shares or 0% of all its holdings. Arizona State Retirement Sys has 0.01% invested in Greif, Inc. (NYSE:GEF). Hightower Advisors Limited Liability reported 4,391 shares stake. 199,355 are owned by Panagora Asset Mgmt. Ls Inv Advisors Ltd Liability Com, Michigan-based fund reported 1,715 shares. Tower Research Cap Ltd Liability (Trc) owns 1,412 shares.

Greif, Inc. is a producer of industrial packaging services and products. The company has market cap of $2.95 billion. The Company’s divisions are Rigid Industrial Packaging & Services; Paper Packaging & Services; Flexible Products & Services, and Land Management. It has a 30.12 P/E ratio. The Rigid Industrial Packaging & Services segment is engaged in the production and sale of rigid industrial packaging products, and services, such as container life cycle management, filling, logistics, warehousing and other packaging services.